Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle–invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations（2022）

引用 2|浏览7

暂无评分

摘要

•The expression and secretion of IL-6 are associated with chemoresistance to gemcitabine in bladder cancer cells.•Serum interleukin-6 might serve as a potential prognostic biomarker for intravesical gemcitabine in T1 non-muscle–invasive bladder cancer.

查看译文

关键词

Bladder cancer,Non-muscle-invasive bladder cancer,IL-6,Cancer biomarker,Cancer recurrence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要